MSB 2.91% $1.06 mesoblast limited

MSB, page-3

  1. 3,884 Posts.
    lightbulb Created with Sketch. 1315
    I've had a look around, Edison, allowing for the market penetration and effectiveness of Entresto still rate Resvascor, subject to P3 results as around US $2 billion US annual sales (plus about half that again in the EU). Some of their analysis is based on this proviso;

    "Use of MPC therapy will be concentrated in those who do not respond adequately to Entresto and who may be undergoing a catheter procedure anyway."

    From page 15 in;

    https://www.edisongroup.com/wp-content/uploads/2019/10/Mesoblast-Increasingly-positive-on-aGvHD.pdf

    Clearly Entresto has revolutionised treatment but it seems there is quite enough space smile.png

    Coming up to the end of February, not too many more months to wait for a clearer direction.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.06
Change
0.030(2.91%)
Mkt cap ! $1.210B
Open High Low Value Volume
$1.05 $1.09 $1.03 $5.796M 5.430M

Buyers (Bids)

No. Vol. Price($)
2 15990 $1.06
 

Sellers (Offers)

Price($) Vol. No.
$1.08 48632 3
View Market Depth
Last trade - 16.10pm 02/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.